Sagimet Biosciences (SGMT) is trading down at $8.83 (-3.39%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on SGMT
One firm's current price target on Sagimet Biosciences: $27 — 206% above the current $8.83. Each is tracked to its date and scored the same way a member's call is.
- Citizens JMP $9.37 → $27 by Oct 2027 Oct 1, 2026 via Investing.com · Citizens JMP's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Sagimet Biosciences revenue & net income history (FY2022–FY2025)
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | $2.00M | — | — |
| Operating income | −$31.1M | −$30.7M | −$54.5M | −$56.9M |
| Operating margin | — | −1537.0% | — | — |
| Net income | −$30.5M | −$27.9M | −$45.6M | −$51.0M |
| Net margin | — | −1393.8% | — | — |
| EPS (diluted) | −$165.20 | −$2.66 | −$1.45 | −$1.58 |
| Balance sheet | ||||
| Cash and equivalents | $158.0K | $75.1M | $75.8M | $35.0M |
| Total assets | $33.0M | $96.7M | $160.3M | $116.5M |
| Total liabilities | $5.36M | $5.65M | $4.45M | $5.10M |
| Shareholders' equity | −$186.9M | $91.1M | $155.8M | $111.4M |
| Cash flow | ||||
| Operating cash flow | −$24.5M | −$23.8M | −$42.4M | −$45.6M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$16.9M | −$18.2M | −$19.9M | −$11.9M | −$14.3M | −$10.8M | −$11.7M | −$15.8M |
| Net income | −$14.6M | −$16.2M | −$18.2M | −$10.4M | −$12.9M | −$9.57M | −$10.7M | −$14.0M |
| EPS (diluted) | −$0.45 | −$0.52 | −$0.56 | −$0.32 | −$0.40 | −$0.30 | −$0.33 | −$0.26 |
| Balance sheet | ||||||||
| Cash and equivalents | $77.0M | $75.8M | $64.7M | $42.3M | $32.5M | $35.0M | $36.6M | $165.9M |
| Total assets | $174.8M | $160.3M | $146.2M | $137.4M | $128.4M | $116.5M | $107.8M | $263.4M |
| Total liabilities | $4.09M | $4.45M | $7.18M | $7.25M | $9.15M | $5.10M | $5.30M | $7.28M |
| Shareholders' equity | $170.7M | $155.8M | $139.0M | $130.2M | $119.3M | $111.4M | $102.5M | $256.2M |
| Cash flow | ||||||||
| Operating cash flow | −$19.6M | −$11.0M | −$14.5M | −$9.10M | −$10.2M | −$11.8M | −$8.61M | −$11.1M |
From Sagimet Biosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Sagimet Biosciences
- Headquarters
- Foster City, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International